Table 2

Multivariable analysis of craniofacial involvement

All patients with and without rituximab n = 4155*All patients without rituximab n = 2814*All patients with rituximab n = 1341*MInT and RICOVER patients without rituximab n = 1022†MInT und RICOVER patients with rituximab n = 1023†
HRP value95% CIHRP value95% CIHRP value95% CIHRP value95% CIHRP value95% CI
EFS      
 LDH > UNV 1.4 <.001 1.3-1.6 1.5 <.001 1.3-1.7 1.7 <.001 1.4-2.1 1.5 <.001 1.3-1.9 1.6 <.001 1.2-2.0 
 Stage III/IV 1.6 <.001 1.5-1.8 1.7 <.001 1.5-1.9 1.6 <.001 1.3-2.1 1.5 <.001 1.2-1.9 1.6 .001 1.2-2.0 
 ECOG >1 1.5 <.001 1.3-1.7 1.5 <.001 1.2-1.7 1.6 <.001 1.2-2.0 1.8 <.001 1.3-2.3 1.7 .001 1.2-2.4 
 Extralymphatic involvement >1 1.2 .026 1.0-1.3 1.1 .108 1.0-1.3 1.2 .186 0.9-1.5 1.4 .008 1.1-1.8 1.1 .666 0.8-1.5 
 Age >60 y 1.4 <.001 1.3-1.6 1.5 <.001 1.3-1.7 1.3 .007 1.1-1.6 1.0 .991 0.8-1.2 1.3 .039 1.0-1.8 
 Craniofacial involvement 0.7 .008 0.6-0.9 0.7 .010 0.5-0.9 0.9 .590 0.6-1.4 0.7 .115 0.4-1.1 0.9 .756 0.6-1.5 
OS      
 LDH > UNV 1.8 <.001 1.6-2.1 1.9 <.001 1.7-2.3 2.3 <.001 1.7-3.1 2.0 <.001 1.5-2.7 2.1 <.001 1.5-3.0 
 Stage III/IV 1.6 <.001 1.4-1.8 1.7 <.001 1.4-2.0 1.6 .003 1.2-2.1 1.3 .055 1.0-1.8 1.4 .066 1.0-2.0 
 ECOG >1 1.7 <.001 1.5-2.0 1.8 <.001 1.5-2.1 1.7 .001 1.3-2.3 1.9 <.001 1.3-2.6 1.9 .001 1.3-2.7 
 Extralymphatic involvement >1 1.2 .041 1.0-1.4 1.2 .121 1.0-1.4 1.2 .227 0.9-1.6 1.8 .001 1.3-2.4 1.2 .478 0.8-1.7 
 Age >60 y 2.2 <.001 2.0-2.6 2.0 <.001 1.7-2.4 2.5 <.001 1.9-3.3 1.6 .003 1.2-2.2 2.8 <.001 1.8-4.3 
 Craniofacial involvement 0.9 .374 0.7-1.2 0.9 .334 0.6-1.2 1.1 .725 0.6-1.9 1.0 .924 0.6-1.8 1.1 .687 0.6-2.0 
All patients with and without rituximab n = 4155*All patients without rituximab n = 2814*All patients with rituximab n = 1341*MInT and RICOVER patients without rituximab n = 1022†MInT und RICOVER patients with rituximab n = 1023†
HRP value95% CIHRP value95% CIHRP value95% CIHRP value95% CIHRP value95% CI
EFS      
 LDH > UNV 1.4 <.001 1.3-1.6 1.5 <.001 1.3-1.7 1.7 <.001 1.4-2.1 1.5 <.001 1.3-1.9 1.6 <.001 1.2-2.0 
 Stage III/IV 1.6 <.001 1.5-1.8 1.7 <.001 1.5-1.9 1.6 <.001 1.3-2.1 1.5 <.001 1.2-1.9 1.6 .001 1.2-2.0 
 ECOG >1 1.5 <.001 1.3-1.7 1.5 <.001 1.2-1.7 1.6 <.001 1.2-2.0 1.8 <.001 1.3-2.3 1.7 .001 1.2-2.4 
 Extralymphatic involvement >1 1.2 .026 1.0-1.3 1.1 .108 1.0-1.3 1.2 .186 0.9-1.5 1.4 .008 1.1-1.8 1.1 .666 0.8-1.5 
 Age >60 y 1.4 <.001 1.3-1.6 1.5 <.001 1.3-1.7 1.3 .007 1.1-1.6 1.0 .991 0.8-1.2 1.3 .039 1.0-1.8 
 Craniofacial involvement 0.7 .008 0.6-0.9 0.7 .010 0.5-0.9 0.9 .590 0.6-1.4 0.7 .115 0.4-1.1 0.9 .756 0.6-1.5 
OS      
 LDH > UNV 1.8 <.001 1.6-2.1 1.9 <.001 1.7-2.3 2.3 <.001 1.7-3.1 2.0 <.001 1.5-2.7 2.1 <.001 1.5-3.0 
 Stage III/IV 1.6 <.001 1.4-1.8 1.7 <.001 1.4-2.0 1.6 .003 1.2-2.1 1.3 .055 1.0-1.8 1.4 .066 1.0-2.0 
 ECOG >1 1.7 <.001 1.5-2.0 1.8 <.001 1.5-2.1 1.7 .001 1.3-2.3 1.9 <.001 1.3-2.6 1.9 .001 1.3-2.7 
 Extralymphatic involvement >1 1.2 .041 1.0-1.4 1.2 .121 1.0-1.4 1.2 .227 0.9-1.6 1.8 .001 1.3-2.4 1.2 .478 0.8-1.7 
 Age >60 y 2.2 <.001 2.0-2.6 2.0 <.001 1.7-2.4 2.5 <.001 1.9-3.3 1.6 .003 1.2-2.2 2.8 <.001 1.8-4.3 
 Craniofacial involvement 0.9 .374 0.7-1.2 0.9 .334 0.6-1.2 1.1 .725 0.6-1.9 1.0 .924 0.6-1.8 1.1 .687 0.6-2.0 
*

According to reference pathology.

†

Intention to treat.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal